沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300142 沃森生物

已收盘 12-05 15:00:00

{"stockData":{"symbol":"300142","market":"SZ","secType":"STK","nameCN":"沃森生物","latestPrice":11.71,"timestamp":1764918231000,"preClose":11.67,"halted":0,"volume":18120936,"delay":0,"changeRate":0.0034,"floatShares":1556000000,"shares":1599000000,"eps":0.0308,"marketStatus":"已收盘","change":0.04,"latestTime":"12-05 15:00:00","open":11.67,"high":11.73,"low":11.51,"amount":211000000,"amplitude":0.0189,"askPrice":11.72,"askSize":1267,"bidPrice":11.71,"bidSize":240,"shortable":0,"etf":0,"ttmEps":0.0308,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":11.67,"symbolType":"stock","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":12.84,"lowLimit":10.5,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1599348541,"isCdr":false,"pbRate":1.93,"roa":"--","peRate":380.194805,"roe":"1.72%","epsLYR":0.0889,"committee":0.093321,"marketValue":18728000000,"turnoverRate":0.0116,"status":0,"floatMarketCap":18220000000},"requestUrl":"/m/hq/s/300142","defaultTab":"news","newsList":[{"id":"2588002439","title":"12月4日沃森生物现1笔大宗交易 机构净买入704.87万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588002439","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588002439?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:58","pubTimestamp":1764838710,"startTime":"0","endTime":"0","summary":"证券之星消息，12月4日沃森生物发生大宗交易，交易数据如下：大宗交易成交价格11.67元，成交60.4万股，成交金额704.87万元，买方营业部为机构专用，卖方营业部为中信证券股份有限公司上海分公司。近三个月该股共发生1笔大宗交易，合计成交6040.0手。该股近期无解禁股上市。截至2025年12月4日收盘，沃森生物(300142)报收于11.67元，下跌0.77%，换手率1.1%，成交量17.04万手，成交额1.99亿元。该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400025517.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300142","BK0070","BK0239","BK0046"],"gpt_icon":0},{"id":"2588725373","title":"沃森生物（300142）披露受让控股子公司少数股权公告，12月01日股价上涨1.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588725373","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588725373?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:48","pubTimestamp":1764582498,"startTime":"0","endTime":"0","summary":"近日，云南沃森生物技术股份有限公司发布公告称，公司于2025年11月28日召开董事会，审议通过受让控股子公司玉溪沃森生物技术有限公司少数股东汇祥越泰（天津）投资合伙企业持有的11.3043%股权，对应注册资本15,683.2722万元，交易价格为163,912.35万元。玉溪沃森为公司核心子公司，主要财务数据显示其具备较强盈利能力。本次交易旨在增强公司对玉溪沃森的控制力，提升决策效率和经营业绩。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100022820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0070","BK0046","300142"],"gpt_icon":0},{"id":"2586789337","title":"沃森生物最新公告：拟16.39亿元受让玉溪沃森11.3%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2586789337","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586789337?lang=zh_cn&edition=full","pubTime":"2025-11-28 19:11","pubTimestamp":1764328278,"startTime":"0","endTime":"0","summary":"沃森生物(300142.SZ)公告称，公司拟受让控股子公司玉溪沃森生物技术有限公司11.3043%股权，交易价格为16.39亿元。玉溪沃森为公司重要的核心子公司，公司目前共有8个疫苗产品获批生产上市销售，其中有7个产品由玉溪沃森生产，玉溪沃森经营状况和财务状况较好，是公司收入和利润的最主要来源。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800031537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0070","300142","BK0077"],"gpt_icon":0},{"id":"2586022242","title":"沃森生物：公司按照相关法规和规范性文件的规定在各期定期报告中披露报告期末的股东人数","url":"https://stock-news.laohu8.com/highlight/detail?id=2586022242","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586022242?lang=zh_cn&edition=full","pubTime":"2025-11-27 19:37","pubTimestamp":1764243420,"startTime":"0","endTime":"0","summary":"证券日报网讯沃森生物11月27日在互动平台回答投资者提问时表示，公司按照相关法规和规范性文件的规定在各期定期报告中披露报告期末的股东人数。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-27/doc-infyvxpy0054284.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-27/doc-infyvxpy0054284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0077","BK0070","300142","BK0046"],"gpt_icon":0},{"id":"2586023254","title":"沃森生物(300142.SZ)子公司收到13价肺炎结合疫苗埃及上市许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2586023254","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586023254?lang=zh_cn&edition=full","pubTime":"2025-11-26 16:43","pubTimestamp":1764146598,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沃森生物(300142.SZ)发布公告，公司子公司玉溪沃森生物技术有限公司(简称“玉溪沃森”)生产的13价肺炎球菌多糖结合疫苗(简称“13价肺炎结合疫苗”)于近日收到埃及药品管理局(EDA)签发的《生物制品上市许可证》，标志着该疫苗获得了埃及的上市许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373867.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"沃森生物(300142.SZ)子公司收到13价肺炎结合疫苗埃及上市许可证","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","BK0046","BK0239","BK0070","300142","BK0077"],"gpt_icon":0},{"id":"2585459901","title":"MIRXES-B早盘涨近8% 携手沃森深耕东盟市场 共建RNA精准医疗创新体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2585459901","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585459901?lang=zh_cn&edition=full","pubTime":"2025-11-24 15:18","pubTimestamp":1763968680,"startTime":"0","endTime":"0","summary":"MIRXES-B(02629)早盘涨近8%，截至发稿，涨2.48%，报53.8港元，成交额1829.42万港元。 消息面上，11月18日，Mirxes觅瑞宣布与沃森生物(300142.SZ)正式签署谅解备忘录，双方将围绕分子诊断与 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251124/c672685724.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0046","BK0077","300142","BK0070","BK0239"],"gpt_icon":0},{"id":"2585853114","title":"沃森生物最新公告：水痘减毒活疫苗临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2585853114","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585853114?lang=zh_cn&edition=full","pubTime":"2025-11-21 18:31","pubTimestamp":1763721106,"startTime":"0","endTime":"0","summary":"沃森生物(300142.SZ)公告称，公司及子公司共同研发的水痘减毒活疫苗临床试验申请获国家药品监督管理局受理。该疫苗采用水痘-带状疱疹病毒减毒株接种人二倍体细胞制成，用于预防水痘。目前，国内已有六家企业的水痘减毒活疫苗获批上市许可。临床试验申请获受理后，还需经批准后方可开展，对公司本年度经营业绩不会产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100029556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0239","BK0046","BK0070","BK0077"],"gpt_icon":0},{"id":"2585994111","title":"港股异动 | MIRXES-B(02629)午后涨超5% 携手沃森生物创建以RNA为中心的预防及精准医疗平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2585994111","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585994111?lang=zh_cn&edition=full","pubTime":"2025-11-21 13:43","pubTimestamp":1763703822,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，MIRXES-B午后涨超5%，截至发稿，涨3.44%，报52.55港元，成交额3273.41万港元。消息面上，MIRXES公布，公司近期与云南沃森生物技术订立谅解备忘录，订约方同意就创建以RNA为中心的预防及精准医疗平台建立战略合作伙伴关系，并涵盖共同开发、临床试验及注册以及销售及分销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02629","BK4505","IE0009354923.USD","BK0070","BK1161","RNA","BK0046","BK0239","BK4585","BK4588","BK4139","BK0077","300142"],"gpt_icon":0},{"id":"2584371751","title":"沃森生物（300142）披露关于注销部分募集资金专用账户的公告，11月20日股价上涨1.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584371751","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584371751?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:05","pubTimestamp":1763647520,"startTime":"0","endTime":"0","summary":"截至2025年11月20日收盘，沃森生物报收于12.54元，较前一交易日上涨1.37%，最新总市值为200.56亿元。该股当日开盘12.61元，最高13.05元，最低12.52元，成交额达6.97亿元，换手率为3.51%。公司近日发布公告称，云南沃森生物技术股份有限公司于2025年11月19日完成注销两个募集资金专用账户，分别为招商银行昆明广福路支行账号871908619110903和云南红塔银行营业部账号1019921000252778。账户注销后，相关监管协议终止，公司已通知独立财务顾问。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000037874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300142","BK0070","BK0077","BK0046"],"gpt_icon":0},{"id":"2579488717","title":"沃森生物：董事长代行董事会秘书职责","url":"https://stock-news.laohu8.com/highlight/detail?id=2579488717","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579488717?lang=zh_cn&edition=full","pubTime":"2025-10-31 08:42","pubTimestamp":1761871339,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物(300142)10月30日在投资者关系平台上答复投资者关心的问题。投资者提问：沃森生物的董秘是否具有担任上市公司董秘的资质？不敢回答吗沃森生物回复：尊敬的投资者，您好！根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》的相关规定，在新任董事会秘书聘任生效前，目前公司暂由董事长代行董事会秘书职责。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100012770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300142","BK0046","BK0077","BK0239"],"gpt_icon":0},{"id":"2579929425","title":"沃森生物：微生态健康业务已进入实施阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2579929425","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579929425?lang=zh_cn&edition=full","pubTime":"2025-10-29 15:30","pubTimestamp":1761723039,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物10月29日在投资者关系平台上答复投资者关心的问题。该领域的临床是否需要药品监督管理局批准，预计产品今年能上市销售吗沃森生物回复：尊敬的投资者，您好！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900026880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0046","BK0077","BK0070","BK0239"],"gpt_icon":0},{"id":"2579846995","title":"图解沃森生物三季报：第三季度单季净利润同比增长40.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579846995","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579846995?lang=zh_cn&edition=full","pubTime":"2025-10-29 02:55","pubTimestamp":1761677747,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物2025年三季报显示，公司主营收入17.19亿元，同比下降19.73%；归母净利润1.63亿元，同比下降36.24%；扣非净利润7054.0万元，同比下降68.5%；其中2025年第三季度，公司单季度主营收入5.65亿元，同比下降20.25%；单季度归母净利润1.2亿元，同比上升40.19%；单季度扣非净利润4209.74万元，同比下降46.0%；负债率17.42%，投资收益278.36万元，财务费用-6183.58万元，毛利率71.69%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900003260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142"],"gpt_icon":0},{"id":"2578364679","title":"股市必读：沃森生物（300142）10月27日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2578364679","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578364679?lang=zh_cn&edition=full","pubTime":"2025-10-28 05:05","pubTimestamp":1761599118,"startTime":"0","endTime":"0","summary":"截至2025年10月27日收盘，沃森生物报收于11.34元，下跌0.09%，换手率1.13%，成交量17.63万手，成交额2.01亿元。董秘最新回复投资者： 贵公司的股价是怎么回事？给人完全是夕阳产业一样？云南地方生物医药企业可有和沃森生物合作并购的消息，一起做大做强董秘： 尊敬的投资者，您好！关于公司对外合作等重大事项的相关信息请以公司披露的公告为准。当日关注点来自交易信息汇总：10月27日主力资金净流出222.4万元，散户资金净流入543.2万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800005703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0070","BK0077","BK0046","BK0239"],"gpt_icon":0},{"id":"2578461536","title":"沃森生物最新公告：呼吸道合胞病毒mRNA疫苗获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2578461536","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578461536?lang=zh_cn&edition=full","pubTime":"2025-10-27 16:53","pubTimestamp":1761555182,"startTime":"0","endTime":"0","summary":"沃森生物(300142.SZ)公告称，公司与复旦大学、上海蓝鹊生物医药有限公司联合研发的呼吸道合胞病毒mRNA疫苗已获得国家药品监督管理局签发的《药物临床试验批准通知书》。该疫苗基于自主研发的“mRNA疫苗技术平台”开发，用于预防呼吸道合胞病毒感染引起的下呼吸道相关疾病。目前，国外已有3款呼吸道合胞病毒疫苗上市，国内尚无同类产品获批。该疫苗获批进入临床试验，但对公司本年度业绩不会产生大的影响，后续确证性III期临床试验结果和药品上市申请结果存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700022036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300142","159646","BK0046","BK0077","BK0239"],"gpt_icon":0},{"id":"2577502275","title":"沃森生物：确保产品供应惠及广大群体","url":"https://stock-news.laohu8.com/highlight/detail?id=2577502275","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577502275?lang=zh_cn&edition=full","pubTime":"2025-10-24 11:33","pubTimestamp":1761276785,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物(300142)10月24日在投资者关系平台上答复投资者关心的问题。投资者提问：自11月10日起，我国将HPV疫苗纳入国家免疫规划，为深入贯彻落实健康中国战略，保障人民群众身体健康,下个月二价HPV纳入免疫规划，沃森生物你的产能准备好了吗？？？对未来股价可有积极促进作用沃森生物回复：尊敬的投资者，您好！公司密切关注相关政策的调整变动情况，将主动采取措施积极响应，确保产品供应，让产品惠及更广大的受众群体。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400015551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0046","BK0070","BK0239","BK0077"],"gpt_icon":0},{"id":"2577335954","title":"沃森生物：依法合规寻求市值管理方式","url":"https://stock-news.laohu8.com/highlight/detail?id=2577335954","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577335954?lang=zh_cn&edition=full","pubTime":"2025-10-22 11:33","pubTimestamp":1761104026,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物10月21日在投资者关系平台上答复投资者关心的问题。贵公司股价年初至今跌幅为百分之五，离上次新低仅一两块钱而已，今年三大板块指数都是15到40个点了，有没有维护公司股价，给投资者信心的操作呢，这股价不是反应公司管理的问题吗沃森生物回复：尊敬的投资者，您好！公司持续关注二级市场情况，将结合自身发展和政策、市场情况，依法合规的寻求切实可行的市值管理方式提升公司的投资价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102200015829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0070","BK0046","BK0239","BK0077"],"gpt_icon":0},{"id":"2576881395","title":"沃森生物：完善生物科技投资生态","url":"https://stock-news.laohu8.com/highlight/detail?id=2576881395","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576881395?lang=zh_cn&edition=full","pubTime":"2025-10-20 11:33","pubTimestamp":1760931198,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物10月20日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘你好，近日港交所宣布将于2025年11月推出恒生生物科技指数期货，旨在为投资者提供更精准的生物科技板块风险管理工具。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102000010655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159837","300142","BK0046","BK0239","BK0077","BK0070"],"gpt_icon":0},{"id":"2576704192","title":"沃森生物：获益生菌技术独占权拓展产品管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2576704192","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576704192?lang=zh_cn&edition=full","pubTime":"2025-10-17 11:36","pubTimestamp":1760672182,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物10月16日在投资者关系平台上答复投资者关心的问题。由于本项目目前仍在进行过程中，关于本项目最终的产品情况请持续关注公司的信息披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700015522.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300142","BK0046","BK0077","BK0239"],"gpt_icon":0},{"id":"2576701078","title":"沃森生物：寻求切实可行的市值管理方式","url":"https://stock-news.laohu8.com/highlight/detail?id=2576701078","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576701078?lang=zh_cn&edition=full","pubTime":"2025-10-17 11:33","pubTimestamp":1760672003,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物10月16日在投资者关系平台上答复投资者关心的问题。公司持续关注二级市场情况，将结合自身发展和政策、市场情况，依法合规的寻求切实可行的市值管理方式提升公司的投资价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700015293.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0070","BK0077","BK0046","BK0239"],"gpt_icon":0},{"id":"2575112224","title":"沃森生物：已获肠道微生物技术独占权","url":"https://stock-news.laohu8.com/highlight/detail?id=2575112224","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575112224?lang=zh_cn&edition=full","pubTime":"2025-10-15 08:40","pubTimestamp":1760488826,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物10月14日在投资者关系平台上答复投资者关心的问题。目前该产品是否有减肥的效果，后期的市场前景如何沃森生物回复：尊敬的投资者，您好！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101500006506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300142","BK0070","BK0046","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1764937676635,"stockEarnings":[{"period":"1week","weight":-0.0442},{"period":"1month","weight":-0.0535},{"period":"3month","weight":-0.0596},{"period":"6month","weight":0.1254},{"period":"1year","weight":-0.1831},{"period":"ytd","weight":-0.033}],"compareEarnings":[{"period":"1week","weight":0.0001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":0.0166},{"period":"6month","weight":0.1449},{"period":"1year","weight":0.1519},{"period":"ytd","weight":0.1563}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"云南沃森生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"114040人(较上一季度减少2.75%)","perCapita":"13643股","listingDate":"2010-11-12","address":"云南省昆明市五华区高新区科新路395号","registeredCapital":"159934万元","survey":"　　云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是人用疫苗。","listedPrice":95},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"沃森生物,300142,沃森生物股票,沃森生物股票老虎,沃森生物股票老虎国际,沃森生物行情,沃森生物股票行情,沃森生物股价,沃森生物股市,沃森生物股票价格,沃森生物股票交易,沃森生物股票购买,沃森生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}